γ-Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide

Kritskiy, Iliya; Volkova, Тatyana V.; Surov, Artem O.; Терехова, И. В.

doi:10.1016/j.carbpol.2019.04.037

Cited by 73 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, compared with pure drugs, the apparent solubility of AZL/CD-MOF was increased by 340 times. Moreover, it is noteworthy that CD-MOFs have been proverbially used in oral, intravenous and even pulmonary DDSs 68 , 93 , 94 .…”

Section: Classification Of Mofsmentioning

confidence: 99%

“…More importantly, co-crystallization does not alter the physicochemical properties of the drug, which can be advantageously exploited to improve the loading efficiency and enhance the drugs solubility. As an example, poorly soluble drugs, such as IBU 184 , lansoprazole 67 , leflunomide 93 and methotrexate (MTX) 185 were successfully embedded in γ -CD-MOFs using the co-crystallization method and the drug loading was equal to or higher than that by an impregnation method.…”

Section: Drug Loading and Characterizationsmentioning

confidence: 99%

See 1 more Smart Citation

Metal-organic frameworks for advanced drug delivery

et al. 2021

Acta Pharmaceutica Sinica B

295

116

View full text Add to dashboard Cite

Metal-organic frameworks (MOFs), comprised of organic ligands and metal ions/metal clusters via coordinative bonds are highly porous, crystalline materials. Their tunable porosity, chemical composition, size and shape, and easy surface functionalization make this large family more and more popular for drug delivery. There is a growing interest over the last decades in the design of engineered MOFs with controlled sizes for a variety of biomedical applications. This article presents an overall review and perspectives of MOFs-based drug delivery systems (DDSs), starting with the MOFs classification adapted for DDSs based on the types of constituting metals and ligands. Then, the synthesis and characterization of MOFs for DDSs are developed, followed by the drug loading strategies, applications, biopharmaceutics and quality control. Importantly, a variety of representative applications of MOFs are detailed from a point of view of applications in pharmaceutics, diseases therapy and advanced DDSs. In particular, the biopharmaceutics and quality control of MOFs-based DDSs are summarized with critical issues to be addressed. Finally, challenges in MOFs development for DDSs are discussed, such as biostability, biosafety, biopharmaceutics and nomenclature.

show abstract

Section: Classification Of Mofsmentioning

confidence: 99%

Section: Drug Loading and Characterizationsmentioning

confidence: 99%

Metal-organic frameworks for advanced drug delivery

et al. 2021

Acta Pharmaceutica Sinica B

295

116

View full text Add to dashboard Cite

show abstract

“…According to the DSC curves, the onset temperatures of decomposition are as follows: T δ = 270 • C, T ε = 292 • C, and T α = 275 • C (however, the exact limits of the heat flow peak are difficult to define). The weight loss for εand α-phases is 48%-49% and 42% for δ-phase, and it can be related to the elimination of hydroxyl groups present in γ-CD and further destruction of glucose units [29][30][31][32]. The decomposition of δ-phase occurs at a higher temperature compared to that of εand α-phases.…”

Section: Thermal Stability Of the New Crystal Phases Of γ-Cd-mof-1mentioning

confidence: 99%

Stability and Phase Transitions of Nontoxic γ-Cyclodextrin-K+ Metal-Organic Framework in Various Solvents

et al. 2020

View full text Add to dashboard Cite

Cyclodextrin (CD) has been used to prepare biocompatible and nontoxic metal-organic frameworks (MOFs) suitable for biomedical applications as drug carriers. In this study, γ-CD/K-based MOF (γ-CD-MOF-1-α) was synthesized and its stability in various solvents was explored by single-crystal X-ray diffractometry (SCXRD) and powder X-ray diffractometry (PXRD). As a result of solvent-induced phase transformations, two novel crystalline phases of γ-CD-MOF-1 were discovered. The newly formed ε- and δ-phases crystallize in orthorhombic and tetragonal symmetry, respectively. In ε-phase, toluene was determined as a guest molecule by SCXRD. Interactions between γ-cyclodextrin and solvent molecules in ε-phase were evaluated using Hirshfeld surface analysis. The thermal stability of the new crystal forms of γ-CD-MOF-1 was analyzed by differential scanning calorimetry and thermogravimetric analysis.

show abstract

“…CD-MOF is the supramolecular assembly, where γ -CDs are used as building blocks and potassium ions play an auxiliary role in the coordination of ( γ -CD) 6 cubic cell units and link them to form a whole three-dimensional topological network crystal 30 , 31 , 32 . Recently, a number of reports on CD-MOF as a promising drug carrier have emerged to load valsartan 33 , folic acid 34 , sucralose 35 , leflunomide 36 , resveratrol 37 , ibuprofen 38 and lansoprazole 39 . However, most of these studies have focused on enhancing the solubility, stability and bioavailability of drugs 40 , 41 .…”

Section: Introductionmentioning

confidence: 99%

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Zhao

Guo

Wang

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

It is essential to develop new carriers for laryngeal drug delivery in light of the lack of therapy in laryngeal related diseases. When the inhalable micron-sized crystals of γ -cyclodextrin metal-organic framework (CD-MOF) was utilized as dry powder inhalers (DPIs) carrier with high fine particle fraction (FPF), it was found in this research that the encapsulation of a glycoside compound, namely, scutellarin (SCU) in CD-MOF could significantly enhance its laryngeal deposition. Firstly, SCU loading into CD-MOF was optimized by incubation. Then, a series of characterizations were carried out to elucidate the mechanisms of drug loading. Finally, the laryngeal deposition rate of CD-MOF was 57.72 ± 2.19% improved by SCU, about two times higher than that of CD-MOF, when it was determined by Next Generation Impactor (NGI) at 65 L/min. As a proof of concept, pharyngolaryngitis therapeutic agent dexamethasone (DEX) had improved laryngeal deposition after being co-encapsulated with SCU in CD-MOF. The molecular simulation demonstrated the configuration of SCU in CD-MOF and its contribution to the free energy of the SCU@CD-MOF, which defined the enhanced laryngeal anchoring. In conclusion, the glycosides-like SCU could effectively enhance the anchoring of CD-MOF particles to the larynx to facilitate the treatment of laryngeal diseases.

show abstract

γ-Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide

Cited by 73 publications

References 36 publications

Metal-organic frameworks for advanced drug delivery

Metal-organic frameworks for advanced drug delivery

Stability and Phase Transitions of Nontoxic γ-Cyclodextrin-K+ Metal-Organic Framework in Various Solvents

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Contact Info

Product

Resources

About